Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.

ABSTRACT: AVETUX is a single arm multicentric phase II investigator initiated trial conducted by the Arbeitsgemeinschaft Internistische Onkologie (AIO) in 11 German sites in patients with previously untreated RAS/BRAF wildtype mCRC independent of MSI status.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Cancer Stage Iv,Colorectal Cancer Metastatic,Colorectal Neoplasms

PROVIDER: 2246010 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq data from Cdk8∆/∆ and wildtype BCR-ABL1p185+ transformed bone marrow cell lines either untreated or treated with SenexinB (4 biological replicates each)

Project description:RNA-seq data from Cdk8∆/∆ and wildtype BCR-ABL1p185+ transformed cell lines either untreated or treated with SenexinB was used to identify kinase-dependent and independent target genes of CDK8

2019-09-20 | GSE136923 | GEO

HU treated cells vs wildtype untreated cells (asynchronized cells)

Project description:DNA replication checkpiont kinase rad3 (human ATM/ATR-like kinase) and cds1 (human CHK2-like kinase) are known to restore stalled replication forks and prevent subsequent cell cycle progression during a replication block imposed by HU-treatment in fission yeast. In order to identify cell cycle-specific exression which are modulated by replication checkpoint kinase rad3 and cds1, microarray approach was used to profile asynchronous and synchronous cells of wildtype and mutants treated and untreated with HU Keywords: HU treated cells vs wildtype untreated cells

2007-12-20 | GSE4280 | GEO

Synthetical lethality of Werner helicase and mismatch repair deficiency is mediated by p53 and PUMA in colon cancer

Project description:Synthetic lethality is a powerful approach for targeting oncogenic drivers in cancer. Recent studies revealed that cancer cells with microsatellite instability (MSI) require Werner (WRN) helicase for survival; however, the underlying mechanism remains unclear. In this study, we found that WRN depletion strongly induced p53 and its downstream apoptotic target PUMA in MSI colorectal cancer (CRC) cells. p53 or PUMA deletion abolished apoptosis induced by WRN depletion in MSI CRC cells. Importantly, correction of MSI abrogated the activation of p53/PUMA and cell killing, while induction of MSI led to sensitivity in isogenic CRC cells. Rare p53-mutant MSI CRC cells are resistant to WRN depletion due to lack of PUMA induction, which could be restored by wildtype p53 knock-in or reconstitution. WRN depletion or treatment with the RecQ helicase inhibitor ML216 suppressed in vitro and in vivo growth of MSI CRCs in a p53/PUMA_x0002_dependent manner. ML216 treatment was efficacious in MSI CRC patient-derived xenografts (PDX). Interestingly, p53 gene remains wildtype in the majority of MSI CRCs. These results indicate a critical role of p53/PUMA-mediated apoptosis in the vulnerability of MSI CRCs to WRN loss, and support WRN as a promising therapeutic target in p53-wildtype MSI CRCs.

2022-10-26 | GSE216455 | GEO

HU treated cells vs wildtype untreated cells (elutriation centrifugation synchronized cells)

2007-12-20 | GSE4283 | GEO

Avelumab added to FOLFIRI plus Cetuximab followed by Avelumab maintenance in patients with previously untreated RAS wild-type colorectal cancer - The phase II FIRE-6-Avelumab study

Project description:Primary objectives: The primary objective of the study is to assess the efficacy of FOLFIRI plus cetuximab incombination with avelumab followed by avelumab maintenance therapy in patients withpreviously untreated RAS/BRAF wild-type mCRC. Primary endpoints: • Progression-free survival (PFS) according to RECIST v1.1

| 2538194 | ecrin-mdr-crc

GaST-seq untreated leaf

Project description:GaST-seq spatial transcriptomics untreated leaf

| PRJEB31314 | ENA

Next Generation Sequencing Facilitates Quantitative Analysis of subcutaneous tumors untreated and treated with doxycycline for 4h to activate shST18

Project description:We report the transcriptome profiling (RNAseq) in hepatoblast-derived tumors, without (untreated) or with ST18 knockdown (4h Doxy) (three independent samples for each condition). We find that ST18 knockdown in hepatoblast-derived tumors affects inflammation-associated genes.

2017-12-22 | GSE72403 | GEO

Roles of relSpn in Stringent Response, Global Regulation, and Virulence of Serotype 2 Streptococcus pneumoniae D39

Project description:Transcriptome analysis of D39 rel+Spn and delta-relSpn strains treated with mupirocin revealed relSpn-independent (translation stress), relSpn-dependent (stringent response), and delta-relSpn-dependent changes suggesting that relSpn and (p)ppGpp amount play wide-ranging homeostatic roles in pneumococcal physiology, besides adjusting macromolecular synthesis and transport in response to nutrient availability. Wildtype and rel deletion mutant (Delta rel) bacteria were grown statically in BHI broth at 37C in an atmosphere of 5% CO2. Cultures were divided in two upon reaching a density of OD620 ~0.1, and lithium mupirocin was added to one culture (t=0) to a final concentration of 100 ng per mL. Treated and untreated cultures were harvested after 20 min further incubation and RNA was extracted by a hot lysis-acid phenol protocol. We performed the following comparisons: Wildtype + mupirocin versus Wildtype untreated (reference); Delta rel + mupirocin versus Delta rel untreated (reference); Delta rel untreated versus Wildtype untreated (reference); Delta rel + mupirocin versus Wildtype + mupirocin (reference). For each comparison, microarray data were obtained from three independent biological replicates and included one dye swap.

2010-05-15 | E-GEOD-14750 | biostudies-arrayexpress

RNASeq analysis of untreated versus treated

Project description:RNASeq analysis of untreated versus treated

| PRJNA497790 | ENA

H2O2-treated and untreated HCT116 cells

Project description:H2O2-treated and untreated HCT116 cells

| PRJNA305862 | ENA